WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Global Generics

Open PDF
  • LMG Names Wilson Sonsini the 2022 "Hatch-Waxman Litigation Firm of the Year – Generic"

    Wilson Sonsini was named "Hatch-Waxman Litigation Firm of the Year – Generic" at the 2022 LMG Life Sciences Awards, and was also recognized under "Hatch-Waxman Impact Cases of the Year" for its work on Celgene v. Mylan (Federal Circuit, 2021) and "Patent Impact Cases of the Year" for its work on ModernaTx v. Arbutus (Federal Circuit, 2021).

In today's fast-growing, highly regulated generic pharmaceutical market, companies increasingly require specialized legal guidance as their products are developed, launched, and litigated. Wilson Sonsini's attorneys address this need by providing expert counsel to companies in the global generics industry, offering sophisticated representation far beyond the scope of general corporate and securities counsel. We have assembled a highly experienced team of experts from a cross-section of the firm's key practice areas, including intellectual property, litigation, antitrust, FDA/regulatory, technology transactions, exports and FCPA, trade secret, and trademark and copyrights.

Led by the former chief legal officer of Mylan Pharmaceuticals, one of the world's leading generic and specialty pharmaceutical companies, our attorneys work closely with our generic pharmaceutical clients' legal and scientific personnel and senior management to understand and meet their specific needs both in the U.S. and abroad. The members of our team, many of whom previously served as in-house general counsel of life sciences companies, possess a deep understanding of the complex international regulatory landscape, particularly as it pertains to life sciences, medical device, and pharmaceutical companies in the rapidly growing Chinese, Indian, and European markets.

Please see below for further information on our full range of offerings for generic pharmaceutical companies.

Strategic Business and Funding Initiatives

With more than 500 innovative life sciences clients and an extensive network of relationships within the private and public equity financing communities, we are uniquely positioned to facilitate connections between generics companies and potential partners and investors. In addition, we have several attorneys with life sciences GC experience who offer a unique perspective on the overall management of in-house legal affairs and strategic business initiatives.

Our attorneys routinely engage in global business development by providing a critical analysis of potential products, including products designed to address needs in niche markets, and product strategies. We work with our clients to identify products with favorable intellectual property assets and regulatory paths to commercialization, as well as potential formulations and delivery-system alternatives for generic drug development.

International Business Opportunities

We have a long and successful history of advising both U.S.- and foreign-based clients—particularly clients in China, India, and Europe—in connection with a variety of international matters, including intellectual property counseling, mergers and acquisitions, joint ventures, foreign investment, branch operations, information technology outsourcing, spin-offs, public and private equity transactions, and capital markets. Of particular relevance to generic pharmaceutical companies, our attorneys are well equipped to provide expert counsel regarding offshore structures, especially those involving the establishment of international R&D and manufacturing facilities.

FDA/Regulatory

The firm's FDA/regulatory attorneys help clients successfully navigate complex regulatory and reimbursement mazes, comply with strictly enforced regulatory and healthcare laws in both the U.S. and abroad, and secure timely approvals and clearances. Our services in this area include representation in negotiations and administrative proceedings, crisis and compliance management, compliance counseling on broadly enforced anti-kickback laws and new patient privacy protection laws, assessment of product development and regulatory approval options, and counseling on advertising and promotional strategies.

Trade Secret

We have one of the country's leading trade secret practices, having provided representation in dozens of cases nationwide in the past several years alone. Our attorneys handle complex trade secret and related disputes—whether between business partners or employees—regarding restrictive covenants, invention assignments, employee mobility, work for hire, UTSA preemption, inevitable disclosure, threatened misappropriation, bad faith, choice of law, and licensing transactions. We possess unique trade secret expertise in both defense- and plaintiff-side cases, and pride ourselves on having raised creative, cutting-edge legal theories that have been adopted in many published cases and subsequently followed by other law firms. We also assist both new and established businesses in developing in-depth protective and preventative strategies.

Employment Law

Working closely with the firm's Trade Secret practice, our employment law attorneys are known for their ability to obtain favorable outcomes in complex, high-exposure cases, as well as to successfully handle EEOC, OFCCP, and wage-and-hour investigations. We have experience with every critical aspect of the employer/employee relationship, including employee mobility and noncompete disputes; recruiting, hiring, and promotion practices; compensation, leave, and wage-and-hour issues; sexual harassment and other forms of discrimination; executive misconduct and performance management; layoffs, restructurings, and terminations; internal and governmental investigations; and union organizing and NLRB proceedings.

Export Controls and FCPA

The firm's export controls and Foreign Corrupt Practices Act (FCPA) practices advise organizations with respect to a broad array of regulatory and compliance issues, including determining how regulations apply to their products and services, preparing for and conducting civil and criminal government investigations and enforcement actions, and developing compliance policies and procedures. Our attorneys regularly work with companies to resolve complex jurisdiction and classification issues, devise licensing strategies, design compliance programs, provide employee compliance training, prepare voluntary disclosures, assist with transactional due diligence, and conduct internal audits and investigations.

We also advise clients on compliance with the Export Administration Regulations (EAR), International Traffic in Arms Regulations (ITAR), and trade and economic sanctions administered by the Office of Foreign Assets Control (OFAC). Further, we regularly provide representation in enforcement-related matters before the Justice Department, the Commerce Department's Bureau of Industry and Security, the State Department's Directorate of Defense Trade Controls, and the Treasury Department's OFAC.

Antitrust and Settlement Strategies

Our internationally recognized Antitrust practice advises clients on the full spectrum of pharmaceutical antitrust issues, including patent settlement counseling and related FTC investigations, private antitrust litigation, Hart-Scott-Rodino merger filings and compliance, and matters involving the intersection of antitrust and intellectual property law. Our team includes attorneys with unparalleled experience within the FTC, including the former director of the FTC's Bureau of Competition, who supervised all FTC pharmaceutical merger and conduct investigations during her tenure, and the former antitrust advisor to FTC Jon Chairman Leibowitz, who was involved in litigating the landmark FTC v. Schering-Plough case and played a leading role in investigations concerning Orange Book listings and patent settlements.

In addition, we have years of experience representing generic pharmaceutical companies in litigation settlements with brand pharmaceutical companies. As a result, we are highly skilled at crafting and negotiating favorable settlements and related licensing arrangements.

Patent Litigation

The firm's robust Generic Pharmaceutical Patent Litigation practice specializes in abbreviated new drug application (ANDA) and Paragraph IV suits. Our patent litigators have participated in more than 25 Hatch-Waxman Act/ANDA litigations, including trials, preliminary injunction proceedings, Federal Circuit appeals, and multi-district litigation.

Our team has significant experience with all types of complex litigation matters—including simultaneous litigation and interference proceedings, and litigation involving simultaneous patent, antitrust, and FDA cases—and complex settlements, licenses, product acquisitions, joint ventures, stock purchase agreements, and a variety of operational agreements (e.g., manufacturing, supply, distribution, marketing, and promotion). We also engage in litigation against or in support of the FDA, manage product development pipelines, file citizen petitions and responses, and conduct strategic due diligence. In addition, our patent litigators provide counseling with respect to patent and FDA issues surrounding new product regulatory filings and product acquisitions.

Patents and Innovations

We have more than 60 professionals with practices dedicated solely to life sciences intellectual property counseling and patent prosecution, with a focus on biotechnology and medical device companies. More than half of these individuals have Ph.D. degrees in biotechnology-related fields, including pharmacology, molecular biology, and organic chemistry.

Our patents and innovations attorneys have an impressive track record of IP value creation, having assisted in developing the IP portfolios covering such inventions as the DNA chip, cancer therapies, nanotechnology, and stem cell technologies. Our experience includes obtaining U.S. and foreign patent clearance for APIs, formulations, and manufacturing processes; integrating IP, regulatory, and commercial strategy for ANDA and 505(b)(2) filings; completing non-infringement and invalidity opinions; integrating citizen-petition filings; preparing pre-litigation strategy and ANDA notice letters; and devising comprehensive, worldwide strategies on reexam, reissue, and oppositions.

Technology Transactions

The firm has more than 70 attorneys dedicated solely to technology transactions. With extensive experience negotiating hundreds of successful business and strategic collaborations, our attorneys have placed the firm's life sciences clients in optimal positions to succeed in today's complex global marketplace. These collaborations include license agreements, joint ventures, co-branding and promotional agreements, R&D agreements, strategic alliances, joint development agreements, co-investment agreements, joint marketing agreements, and manufacturing, supply, and distribution agreements.

Trademark and Copyright

Our trademark and copyright attorneys provide clients with sophisticated and aggressive strategic counseling, transactional, and litigation expertise on matters involving trademark, copyright, advertising, Internet, retail, media, and consumer law. We counsel clients on the selection, protection, and enforcement of company names, brand names, slogans, and trade dress for U.S. and worldwide markets, including registration and licensing, and have engaged in cutting-edge litigation in U.S. courts on trademark, trade name, trade dress, domain name, copyright, right of publicity/privacy, and unfair competition issues. We also represent clients in connection with trademark opposition and cancellation proceedings in both the U.S. and abroad.

FDA/Regulatory

The firm's FDA/regulatory attorneys help clients successfully navigate complex regulatory and reimbursement mazes, comply with strictly enforced regulatory and healthcare laws in both the U.S. and abroad, and secure timely approvals and clearances. Our services in this area include representation in negotiations and administrative proceedings, crisis and compliance management, compliance counseling on broadly enforced anti-kickback laws and new patient privacy protection laws, assessment of product development and regulatory approval options, and counseling on advertising and promotional strategies.

Trade Secret

We have one of the country's leading trade secret practices, having provided representation in dozens of cases nationwide in the past several years alone. Our attorneys handle complex trade secret and related disputes—whether between business partners or employees—regarding restrictive covenants, invention assignments, employee mobility, work for hire, UTSA preemption, inevitable disclosure, threatened misappropriation, bad faith, choice of law, and licensing transactions. We possess unique trade secret expertise in both defense- and plaintiff-side cases, and pride ourselves on having raised creative, cutting-edge legal theories that have been adopted in many published cases and subsequently followed by other law firms. We also assist both new and established businesses in developing in-depth protective and preventative strategies.

Employment Law

Working closely with the firm's Trade Secret practice, our employment law attorneys are known for their ability to obtain favorable outcomes in complex, high-exposure cases, as well as to successfully handle EEOC, OFCCP, and wage-and-hour investigations. We have experience with every critical aspect of the employer/employee relationship, including employee mobility and noncompete disputes; recruiting, hiring, and promotion practices; compensation, leave, and wage-and-hour issues; sexual harassment and other forms of discrimination; executive misconduct and performance management; layoffs, restructurings, and terminations; internal and governmental investigations; and union organizing and NLRB proceedings.

Export Controls and FCPA

The firm's export controls and Foreign Corrupt Practices Act (FCPA) practices advise organizations with respect to a broad array of regulatory and compliance issues, including determining how regulations apply to their products and services, preparing for and conducting civil and criminal government investigations and enforcement actions, and developing compliance policies and procedures. Our attorneys regularly work with companies to resolve complex jurisdiction and classification issues, devise licensing strategies, design compliance programs, provide employee compliance training, prepare voluntary disclosures, assist with transactional due diligence, and conduct internal audits and investigations.

We also advise clients on compliance with the Export Administration Regulations (EAR), International Traffic in Arms Regulations (ITAR), and trade and economic sanctions administered by the Office of Foreign Assets Control (OFAC). Further, we regularly provide representation in enforcement-related matters before the Justice Department, the Commerce Department's Bureau of Industry and Security, the State Department's Directorate of Defense Trade Controls, and the Treasury Department's OFAC.

Antitrust and Settlement Strategies

Our internationally recognized Antitrust practice advises clients on the full spectrum of pharmaceutical antitrust issues, including patent settlement counseling and related FTC investigations, private antitrust litigation, Hart-Scott-Rodino merger filings and compliance, and matters involving the intersection of antitrust and intellectual property law. Our team includes attorneys with unparalleled experience within the FTC, including the former director of the FTC's Bureau of Competition, who supervised all FTC pharmaceutical merger and conduct investigations during her tenure, and the former antitrust advisor to FTC Jon Chairman Leibowitz, who was involved in litigating the landmark FTC v. Schering-Plough case and played a leading role in investigations concerning Orange Book listings and patent settlements.

In addition, we have years of experience representing generic pharmaceutical companies in litigation settlements with brand pharmaceutical companies. As a result, we are highly skilled at crafting and negotiating favorable settlements and related licensing arrangements.

Patent Litigation

The firm's robust Generic Pharmaceutical Patent Litigation practice specializes in abbreviated new drug application (ANDA) and Paragraph IV suits. Our patent litigators have participated in more than 25 Hatch-Waxman Act/ANDA litigations, including trials, preliminary injunction proceedings, Federal Circuit appeals, and multi-district litigation.

Our team has significant experience with all types of complex litigation matters—including simultaneous litigation and interference proceedings, and litigation involving simultaneous patent, antitrust, and FDA cases—and complex settlements, licenses, product acquisitions, joint ventures, stock purchase agreements, and a variety of operational agreements (e.g., manufacturing, supply, distribution, marketing, and promotion). We also engage in litigation against or in support of the FDA, manage product development pipelines, file citizen petitions and responses, and conduct strategic due diligence. In addition, our patent litigators provide counseling with respect to patent and FDA issues surrounding new product regulatory filings and product acquisitions.

Patents and Innovations

We have more than 60 professionals with practices dedicated solely to life sciences intellectual property counseling and patent prosecution, with a focus on biotechnology and medical device companies. More than half of these individuals have Ph.D. degrees in biotechnology-related fields, including pharmacology, molecular biology, and organic chemistry.

Our patents and innovations attorneys have an impressive track record of IP value creation, having assisted in developing the IP portfolios covering such inventions as the DNA chip, cancer therapies, nanotechnology, and stem cell technologies. Our experience includes obtaining U.S. and foreign patent clearance for APIs, formulations, and manufacturing processes; integrating IP, regulatory, and commercial strategy for ANDA and 505(b)(2) filings; completing non-infringement and invalidity opinions; integrating citizen-petition filings; preparing pre-litigation strategy and ANDA notice letters; and devising comprehensive, worldwide strategies on reexam, reissue, and oppositions.

Technology Transactions

The firm has more than 70 attorneys dedicated solely to technology transactions. With extensive experience negotiating hundreds of successful business and strategic collaborations, our attorneys have placed the firm's life sciences clients in optimal positions to succeed in today's complex global marketplace. These collaborations include license agreements, joint ventures, co-branding and promotional agreements, R&D agreements, strategic alliances, joint development agreements, co-investment agreements, joint marketing agreements, and manufacturing, supply, and distribution agreements.

Trademark and Copyright

Our trademark and copyright attorneys provide clients with sophisticated and aggressive strategic counseling, transactional, and litigation expertise on matters involving trademark, copyright, advertising, Internet, retail, media, and consumer law. We counsel clients on the selection, protection, and enforcement of company names, brand names, slogans, and trade dress for U.S. and worldwide markets, including registration and licensing, and have engaged in cutting-edge litigation in U.S. courts on trademark, trade name, trade dress, domain name, copyright, right of publicity/privacy, and unfair competition issues. We also represent clients in connection with trademark opposition and cancellation proceedings in both the U.S. and abroad.

Overview

In today's fast-growing, highly regulated generic pharmaceutical market, companies increasingly require specialized legal guidance as their products are developed, launched, and litigated. Wilson Sonsini's attorneys address this need by providing expert counsel to companies in the global generics industry, offering sophisticated representation far beyond the scope of general corporate and securities counsel. We have assembled a highly experienced team of experts from a cross-section of the firm's key practice areas, including intellectual property, litigation, antitrust, FDA/regulatory, technology transactions, exports and FCPA, trade secret, and trademark and copyrights.

Led by the former chief legal officer of Mylan Pharmaceuticals, one of the world's leading generic and specialty pharmaceutical companies, our attorneys work closely with our generic pharmaceutical clients' legal and scientific personnel and senior management to understand and meet their specific needs both in the U.S. and abroad. The members of our team, many of whom previously served as in-house general counsel of life sciences companies, possess a deep understanding of the complex international regulatory landscape, particularly as it pertains to life sciences, medical device, and pharmaceutical companies in the rapidly growing Chinese, Indian, and European markets.

Please see below for further information on our full range of offerings for generic pharmaceutical companies.

Strategic Business and Funding Initiatives

With more than 500 innovative life sciences clients and an extensive network of relationships within the private and public equity financing communities, we are uniquely positioned to facilitate connections between generics companies and potential partners and investors. In addition, we have several attorneys with life sciences GC experience who offer a unique perspective on the overall management of in-house legal affairs and strategic business initiatives.

Our attorneys routinely engage in global business development by providing a critical analysis of potential products, including products designed to address needs in niche markets, and product strategies. We work with our clients to identify products with favorable intellectual property assets and regulatory paths to commercialization, as well as potential formulations and delivery-system alternatives for generic drug development.

International Business Opportunities

We have a long and successful history of advising both U.S.- and foreign-based clients—particularly clients in China, India, and Europe—in connection with a variety of international matters, including intellectual property counseling, mergers and acquisitions, joint ventures, foreign investment, branch operations, information technology outsourcing, spin-offs, public and private equity transactions, and capital markets. Of particular relevance to generic pharmaceutical companies, our attorneys are well equipped to provide expert counsel regarding offshore structures, especially those involving the establishment of international R&D and manufacturing facilities.

FDA/Regulatory

The firm's FDA/regulatory attorneys help clients successfully navigate complex regulatory and reimbursement mazes, comply with strictly enforced regulatory and healthcare laws in both the U.S. and abroad, and secure timely approvals and clearances. Our services in this area include representation in negotiations and administrative proceedings, crisis and compliance management, compliance counseling on broadly enforced anti-kickback laws and new patient privacy protection laws, assessment of product development and regulatory approval options, and counseling on advertising and promotional strategies.

Trade Secret

We have one of the country's leading trade secret practices, having provided representation in dozens of cases nationwide in the past several years alone. Our attorneys handle complex trade secret and related disputes—whether between business partners or employees—regarding restrictive covenants, invention assignments, employee mobility, work for hire, UTSA preemption, inevitable disclosure, threatened misappropriation, bad faith, choice of law, and licensing transactions. We possess unique trade secret expertise in both defense- and plaintiff-side cases, and pride ourselves on having raised creative, cutting-edge legal theories that have been adopted in many published cases and subsequently followed by other law firms. We also assist both new and established businesses in developing in-depth protective and preventative strategies.

Employment Law

Working closely with the firm's Trade Secret practice, our employment law attorneys are known for their ability to obtain favorable outcomes in complex, high-exposure cases, as well as to successfully handle EEOC, OFCCP, and wage-and-hour investigations. We have experience with every critical aspect of the employer/employee relationship, including employee mobility and noncompete disputes; recruiting, hiring, and promotion practices; compensation, leave, and wage-and-hour issues; sexual harassment and other forms of discrimination; executive misconduct and performance management; layoffs, restructurings, and terminations; internal and governmental investigations; and union organizing and NLRB proceedings.

Export Controls and FCPA

The firm's export controls and Foreign Corrupt Practices Act (FCPA) practices advise organizations with respect to a broad array of regulatory and compliance issues, including determining how regulations apply to their products and services, preparing for and conducting civil and criminal government investigations and enforcement actions, and developing compliance policies and procedures. Our attorneys regularly work with companies to resolve complex jurisdiction and classification issues, devise licensing strategies, design compliance programs, provide employee compliance training, prepare voluntary disclosures, assist with transactional due diligence, and conduct internal audits and investigations.

We also advise clients on compliance with the Export Administration Regulations (EAR), International Traffic in Arms Regulations (ITAR), and trade and economic sanctions administered by the Office of Foreign Assets Control (OFAC). Further, we regularly provide representation in enforcement-related matters before the Justice Department, the Commerce Department's Bureau of Industry and Security, the State Department's Directorate of Defense Trade Controls, and the Treasury Department's OFAC.

Antitrust and Settlement Strategies

Our internationally recognized Antitrust practice advises clients on the full spectrum of pharmaceutical antitrust issues, including patent settlement counseling and related FTC investigations, private antitrust litigation, Hart-Scott-Rodino merger filings and compliance, and matters involving the intersection of antitrust and intellectual property law. Our team includes attorneys with unparalleled experience within the FTC, including the former director of the FTC's Bureau of Competition, who supervised all FTC pharmaceutical merger and conduct investigations during her tenure, and the former antitrust advisor to FTC Jon Chairman Leibowitz, who was involved in litigating the landmark FTC v. Schering-Plough case and played a leading role in investigations concerning Orange Book listings and patent settlements.

In addition, we have years of experience representing generic pharmaceutical companies in litigation settlements with brand pharmaceutical companies. As a result, we are highly skilled at crafting and negotiating favorable settlements and related licensing arrangements.

Patent Litigation

The firm's robust Generic Pharmaceutical Patent Litigation practice specializes in abbreviated new drug application (ANDA) and Paragraph IV suits. Our patent litigators have participated in more than 25 Hatch-Waxman Act/ANDA litigations, including trials, preliminary injunction proceedings, Federal Circuit appeals, and multi-district litigation.

Our team has significant experience with all types of complex litigation matters—including simultaneous litigation and interference proceedings, and litigation involving simultaneous patent, antitrust, and FDA cases—and complex settlements, licenses, product acquisitions, joint ventures, stock purchase agreements, and a variety of operational agreements (e.g., manufacturing, supply, distribution, marketing, and promotion). We also engage in litigation against or in support of the FDA, manage product development pipelines, file citizen petitions and responses, and conduct strategic due diligence. In addition, our patent litigators provide counseling with respect to patent and FDA issues surrounding new product regulatory filings and product acquisitions.

Patents and Innovations

We have more than 60 professionals with practices dedicated solely to life sciences intellectual property counseling and patent prosecution, with a focus on biotechnology and medical device companies. More than half of these individuals have Ph.D. degrees in biotechnology-related fields, including pharmacology, molecular biology, and organic chemistry.

Our patents and innovations attorneys have an impressive track record of IP value creation, having assisted in developing the IP portfolios covering such inventions as the DNA chip, cancer therapies, nanotechnology, and stem cell technologies. Our experience includes obtaining U.S. and foreign patent clearance for APIs, formulations, and manufacturing processes; integrating IP, regulatory, and commercial strategy for ANDA and 505(b)(2) filings; completing non-infringement and invalidity opinions; integrating citizen-petition filings; preparing pre-litigation strategy and ANDA notice letters; and devising comprehensive, worldwide strategies on reexam, reissue, and oppositions.

Technology Transactions

The firm has more than 70 attorneys dedicated solely to technology transactions. With extensive experience negotiating hundreds of successful business and strategic collaborations, our attorneys have placed the firm's life sciences clients in optimal positions to succeed in today's complex global marketplace. These collaborations include license agreements, joint ventures, co-branding and promotional agreements, R&D agreements, strategic alliances, joint development agreements, co-investment agreements, joint marketing agreements, and manufacturing, supply, and distribution agreements.

Trademark and Copyright

Our trademark and copyright attorneys provide clients with sophisticated and aggressive strategic counseling, transactional, and litigation expertise on matters involving trademark, copyright, advertising, Internet, retail, media, and consumer law. We counsel clients on the selection, protection, and enforcement of company names, brand names, slogans, and trade dress for U.S. and worldwide markets, including registration and licensing, and have engaged in cutting-edge litigation in U.S. courts on trademark, trade name, trade dress, domain name, copyright, right of publicity/privacy, and unfair competition issues. We also represent clients in connection with trademark opposition and cancellation proceedings in both the U.S. and abroad.

FDA/Regulatory

The firm's FDA/regulatory attorneys help clients successfully navigate complex regulatory and reimbursement mazes, comply with strictly enforced regulatory and healthcare laws in both the U.S. and abroad, and secure timely approvals and clearances. Our services in this area include representation in negotiations and administrative proceedings, crisis and compliance management, compliance counseling on broadly enforced anti-kickback laws and new patient privacy protection laws, assessment of product development and regulatory approval options, and counseling on advertising and promotional strategies.

Trade Secret

We have one of the country's leading trade secret practices, having provided representation in dozens of cases nationwide in the past several years alone. Our attorneys handle complex trade secret and related disputes—whether between business partners or employees—regarding restrictive covenants, invention assignments, employee mobility, work for hire, UTSA preemption, inevitable disclosure, threatened misappropriation, bad faith, choice of law, and licensing transactions. We possess unique trade secret expertise in both defense- and plaintiff-side cases, and pride ourselves on having raised creative, cutting-edge legal theories that have been adopted in many published cases and subsequently followed by other law firms. We also assist both new and established businesses in developing in-depth protective and preventative strategies.

Employment Law

Working closely with the firm's Trade Secret practice, our employment law attorneys are known for their ability to obtain favorable outcomes in complex, high-exposure cases, as well as to successfully handle EEOC, OFCCP, and wage-and-hour investigations. We have experience with every critical aspect of the employer/employee relationship, including employee mobility and noncompete disputes; recruiting, hiring, and promotion practices; compensation, leave, and wage-and-hour issues; sexual harassment and other forms of discrimination; executive misconduct and performance management; layoffs, restructurings, and terminations; internal and governmental investigations; and union organizing and NLRB proceedings.

Export Controls and FCPA

The firm's export controls and Foreign Corrupt Practices Act (FCPA) practices advise organizations with respect to a broad array of regulatory and compliance issues, including determining how regulations apply to their products and services, preparing for and conducting civil and criminal government investigations and enforcement actions, and developing compliance policies and procedures. Our attorneys regularly work with companies to resolve complex jurisdiction and classification issues, devise licensing strategies, design compliance programs, provide employee compliance training, prepare voluntary disclosures, assist with transactional due diligence, and conduct internal audits and investigations.

We also advise clients on compliance with the Export Administration Regulations (EAR), International Traffic in Arms Regulations (ITAR), and trade and economic sanctions administered by the Office of Foreign Assets Control (OFAC). Further, we regularly provide representation in enforcement-related matters before the Justice Department, the Commerce Department's Bureau of Industry and Security, the State Department's Directorate of Defense Trade Controls, and the Treasury Department's OFAC.

Antitrust and Settlement Strategies

Our internationally recognized Antitrust practice advises clients on the full spectrum of pharmaceutical antitrust issues, including patent settlement counseling and related FTC investigations, private antitrust litigation, Hart-Scott-Rodino merger filings and compliance, and matters involving the intersection of antitrust and intellectual property law. Our team includes attorneys with unparalleled experience within the FTC, including the former director of the FTC's Bureau of Competition, who supervised all FTC pharmaceutical merger and conduct investigations during her tenure, and the former antitrust advisor to FTC Jon Chairman Leibowitz, who was involved in litigating the landmark FTC v. Schering-Plough case and played a leading role in investigations concerning Orange Book listings and patent settlements.

In addition, we have years of experience representing generic pharmaceutical companies in litigation settlements with brand pharmaceutical companies. As a result, we are highly skilled at crafting and negotiating favorable settlements and related licensing arrangements.

Patent Litigation

The firm's robust Generic Pharmaceutical Patent Litigation practice specializes in abbreviated new drug application (ANDA) and Paragraph IV suits. Our patent litigators have participated in more than 25 Hatch-Waxman Act/ANDA litigations, including trials, preliminary injunction proceedings, Federal Circuit appeals, and multi-district litigation.

Our team has significant experience with all types of complex litigation matters—including simultaneous litigation and interference proceedings, and litigation involving simultaneous patent, antitrust, and FDA cases—and complex settlements, licenses, product acquisitions, joint ventures, stock purchase agreements, and a variety of operational agreements (e.g., manufacturing, supply, distribution, marketing, and promotion). We also engage in litigation against or in support of the FDA, manage product development pipelines, file citizen petitions and responses, and conduct strategic due diligence. In addition, our patent litigators provide counseling with respect to patent and FDA issues surrounding new product regulatory filings and product acquisitions.

Patents and Innovations

We have more than 60 professionals with practices dedicated solely to life sciences intellectual property counseling and patent prosecution, with a focus on biotechnology and medical device companies. More than half of these individuals have Ph.D. degrees in biotechnology-related fields, including pharmacology, molecular biology, and organic chemistry.

Our patents and innovations attorneys have an impressive track record of IP value creation, having assisted in developing the IP portfolios covering such inventions as the DNA chip, cancer therapies, nanotechnology, and stem cell technologies. Our experience includes obtaining U.S. and foreign patent clearance for APIs, formulations, and manufacturing processes; integrating IP, regulatory, and commercial strategy for ANDA and 505(b)(2) filings; completing non-infringement and invalidity opinions; integrating citizen-petition filings; preparing pre-litigation strategy and ANDA notice letters; and devising comprehensive, worldwide strategies on reexam, reissue, and oppositions.

Technology Transactions

The firm has more than 70 attorneys dedicated solely to technology transactions. With extensive experience negotiating hundreds of successful business and strategic collaborations, our attorneys have placed the firm's life sciences clients in optimal positions to succeed in today's complex global marketplace. These collaborations include license agreements, joint ventures, co-branding and promotional agreements, R&D agreements, strategic alliances, joint development agreements, co-investment agreements, joint marketing agreements, and manufacturing, supply, and distribution agreements.

Trademark and Copyright

Our trademark and copyright attorneys provide clients with sophisticated and aggressive strategic counseling, transactional, and litigation expertise on matters involving trademark, copyright, advertising, Internet, retail, media, and consumer law. We counsel clients on the selection, protection, and enforcement of company names, brand names, slogans, and trade dress for U.S. and worldwide markets, including registration and licensing, and have engaged in cutting-edge litigation in U.S. courts on trademark, trade name, trade dress, domain name, copyright, right of publicity/privacy, and unfair competition issues. We also represent clients in connection with trademark opposition and cancellation proceedings in both the U.S. and abroad.

Alerts
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Alerts
Double Dose of New Tariffs: President Prescribes New Pharmaceuticals and Metals Tariffs
On April 2, 2026, President Trump issued two presidential proclamations: a proclamation imposing Section 232 tariffs on certain branded pharmaceutical products and associated active pharmaceutical ingredients (APIs) (the Pharmaceuticals Proclamation), and a proclamation modifying the Section 232 steel, aluminum, and copper tariffs (the Metals Proclamation).
Alerts
New FDA Draft Guidance Clarifies Three-Year Exclusivity for New Clinical Investigations
Key Takeaways
Client Highlights
Wilson Sonsini Defends Win in Xarelto Appeal
On September 23, 2025, the U.S. Court of Appeals affirmed a decision of the Patent Trial and Appeal Board (PTAB) holding key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan Pharmaceuticals in the challenge before the PTAB and at the Federal Circuit. 
Alerts
FDA Launches PreCheck and Advanced Manufacturing Technologies Designation Programs to Strengthen U.S. Drug Manufacturing
Key Takeaways
View All
Insights
Alerts
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Alerts
Double Dose of New Tariffs: President Prescribes New Pharmaceuticals and Metals Tariffs
On April 2, 2026, President Trump issued two presidential proclamations: a proclamation imposing Section 232 tariffs on certain branded pharmaceutical products and associated active pharmaceutical ingredients (APIs) (the Pharmaceuticals Proclamation), and a proclamation modifying the Section 232 steel, aluminum, and copper tariffs (the Metals Proclamation).
Alerts
New FDA Draft Guidance Clarifies Three-Year Exclusivity for New Clinical Investigations
Key Takeaways
Client Highlights
Wilson Sonsini Defends Win in Xarelto Appeal
On September 23, 2025, the U.S. Court of Appeals affirmed a decision of the Patent Trial and Appeal Board (PTAB) holding key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan Pharmaceuticals in the challenge before the PTAB and at the Federal Circuit. 
Alerts
FDA Launches PreCheck and Advanced Manufacturing Technologies Designation Programs to Strengthen U.S. Drug Manufacturing
Key Takeaways
View All
Affiliated Programs
London Forum on Global Economic Sanctions
The London Forum on Global Economic Sanctions 2023 program will provide attendees with the most up-to-date developments in economic sanctions from leading financial services organizations as well as global exporters. This is a must-attend for sanctions and financial crime prevention experts.
Affiliated Programs
IAPP Europe Data Protection Congress
Europe’s top gathering of data protection professionals is returning for its 12th year in Brussels. The International Association of Privacy Professionals (IAPP) Europe Data Protection Congress 2023 is the place for delegates to gain insights and working knowledge that will allow you to set a course for the future of your data protection operation. Wilson Sonsini is proud to sponsor this year’s event. To learn more about the conference, and the IAPP, click here.
Speaking Engagements
Connecting MadTech and Money
MadTechMoney brings together ad tech/martech founders and the investment community (private equity, venture capital, corporate development and strategic investors) to discuss key investment trends.
Affiliated Programs
GP Bullhound Allstars 2023
Allstars recognizes and celebrates the successes and achievements within Europe’s technology universe, drawing attention to those who are shaping the industry’s future and creating the global winners of tomorrow. Dubbed the ‘Oscars of the tech world’ Allstars has stood strong as one of Europe’s leading events for the last 20 years.
Speaking Engagements
Seedlegal’s Raise Your “A” Game
Join Seedlegal’s for a tactical and informative panel discussion on the journey of raising seed funding all the way to series A. This event, hosted with HSBC Innovation Banking and in partnership with Hiscox and Crowdcube, brings together a group of seasoned entrepreneurs, angel investors, and venture capitalists who will willingly share their personal triumphs and failures, giving you data-driven insights into the world of startup funding.
Affiliated Programs
London Tech Drinks (Founders & Operators)
Meet up with us at the London Tech Drinks - Founders and Operators Edition where we’ll bring together more than 100 exceptional Founders and Operators for a relaxed and informal get together.
View All
Events
Affiliated Programs
London Forum on Global Economic Sanctions
The London Forum on Global Economic Sanctions 2023 program will provide attendees with the most up-to-date developments in economic sanctions from leading financial services organizations as well as global exporters. This is a must-attend for sanctions and financial crime prevention experts.
Affiliated Programs
IAPP Europe Data Protection Congress
Europe’s top gathering of data protection professionals is returning for its 12th year in Brussels. The International Association of Privacy Professionals (IAPP) Europe Data Protection Congress 2023 is the place for delegates to gain insights and working knowledge that will allow you to set a course for the future of your data protection operation. Wilson Sonsini is proud to sponsor this year’s event. To learn more about the conference, and the IAPP, click here.
Speaking Engagements
Connecting MadTech and Money
MadTechMoney brings together ad tech/martech founders and the investment community (private equity, venture capital, corporate development and strategic investors) to discuss key investment trends.
Affiliated Programs
GP Bullhound Allstars 2023
Allstars recognizes and celebrates the successes and achievements within Europe’s technology universe, drawing attention to those who are shaping the industry’s future and creating the global winners of tomorrow. Dubbed the ‘Oscars of the tech world’ Allstars has stood strong as one of Europe’s leading events for the last 20 years.
Speaking Engagements
Seedlegal’s Raise Your “A” Game
Join Seedlegal’s for a tactical and informative panel discussion on the journey of raising seed funding all the way to series A. This event, hosted with HSBC Innovation Banking and in partnership with Hiscox and Crowdcube, brings together a group of seasoned entrepreneurs, angel investors, and venture capitalists who will willingly share their personal triumphs and failures, giving you data-driven insights into the world of startup funding.
Affiliated Programs
London Tech Drinks (Founders & Operators)
Meet up with us at the London Tech Drinks - Founders and Operators Edition where we’ll bring together more than 100 exceptional Founders and Operators for a relaxed and informal get together.
View All
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Nellie J. Brutocao
Partner
San Diego
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies in intellectual property and commercial transactions, including strategic alliances, research and development collaborations, technology licenses and acquisitions, supply, distribution and manufacturing agreements, sponsored research agreements, clinical trials arrangements, material transfer agreements, and co-promotion arrangements. She has also represented life sciences companies in complex commercial and patent disputes, including Hatch-Waxman litigation.
  • Technology Transactions
View Profile
Ian B. Edvalson
Partner
Palo Alto
Ian advises life sciences clients in strategic alliances, agreements, arrangements, collaborations, and joint ventures.
  • Technology Transactions
View Profile
Farah B. Gerdes
Partner
Boston
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
  • Technology Transactions
View Profile
Tina Hanson
Partner
San Francisco
Kristina Hanson is a partner in the San Francisco office of Wilson Sonsini Goodrich & Rosati. Her practice primarily focuses on intellectual property litigation, with an emphasis on pharmaceutical patent matters arising under the Hatch-Waxman Act. She has represented clients in a variety of pharmaceutical matters, from pre-trial strategy counseling through appeals.
  • Litigation
View Profile
Andrew D. Hoffman
Partner
Palo Alto
Andrew’s practice focuses on corporate and securities work for companies at all stages of growth, as well as for financial institutions, venture capital firms, and other investors.
  • Corporate
View Profile
Norm Hovijitra
Partner
Dr. Norm Hovijitra is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. He advises emerging and established companies in the life sciences industry on legal and business issues associated with the development, manufacture, and commercialization of their products and technologies, including matters relating to intellectual property strategy and patents.
  • Technology Transactions
View Profile
Alex Key
Partner
Palo Alto
Alex focuses on representing clients in the biotechnology, pharmaceutical, medical device, diagnostic, and digital health industries.
  • Technology Transactions
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
View All
People
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Nellie J. Brutocao
Partner
San Diego
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies in intellectual property and commercial transactions, including strategic alliances, research and development collaborations, technology licenses and acquisitions, supply, distribution and manufacturing agreements, sponsored research agreements, clinical trials arrangements, material transfer agreements, and co-promotion arrangements. She has also represented life sciences companies in complex commercial and patent disputes, including Hatch-Waxman litigation.
  • Technology Transactions
View Profile
Ian B. Edvalson
Partner
Palo Alto
Ian advises life sciences clients in strategic alliances, agreements, arrangements, collaborations, and joint ventures.
  • Technology Transactions
View Profile
Farah B. Gerdes
Partner
Boston
Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.
  • Technology Transactions
View Profile
Tina Hanson
Partner
San Francisco
Kristina Hanson is a partner in the San Francisco office of Wilson Sonsini Goodrich & Rosati. Her practice primarily focuses on intellectual property litigation, with an emphasis on pharmaceutical patent matters arising under the Hatch-Waxman Act. She has represented clients in a variety of pharmaceutical matters, from pre-trial strategy counseling through appeals.
  • Litigation
View Profile
Andrew D. Hoffman
Partner
Palo Alto
Andrew’s practice focuses on corporate and securities work for companies at all stages of growth, as well as for financial institutions, venture capital firms, and other investors.
  • Corporate
View Profile
Norm Hovijitra
Partner
Dr. Norm Hovijitra is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. He advises emerging and established companies in the life sciences industry on legal and business issues associated with the development, manufacture, and commercialization of their products and technologies, including matters relating to intellectual property strategy and patents.
  • Technology Transactions
View Profile
Alex Key
Partner
Palo Alto
Alex focuses on representing clients in the biotechnology, pharmaceutical, medical device, diagnostic, and digital health industries.
  • Technology Transactions
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
View All
Related Practices
  • Antitrust and Competition
  • Corporate Life Sciences
  • Patent Litigation
  • Life Sciences Business Advisory Practice
Related Industries
  • Life Sciences
Recent Insights
Alerts
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
Learn More
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Learn More
View All
Recent Events
Affiliated Programs
London Forum on Global Economic Sanctions
The London Forum on Global Economic Sanctions 2023 program will provide attendees with the most up-to-date developments in economic sanctions from leading financial services organizations as well as global exporters. This is a must-attend for sanctions and financial crime prevention experts.
Learn More
Affiliated Programs
IAPP Europe Data Protection Congress
Europe’s top gathering of data protection professionals is returning for its 12th year in Brussels. The International Association of Privacy Professionals (IAPP) Europe Data Protection Congress 2023 is the place for delegates to gain insights and working knowledge that will allow you to set a course for the future of your data protection operation. Wilson Sonsini is proud to sponsor this year’s event. To learn more about the conference, and the IAPP, click here.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.